French Breast Cancer Intergroupe - Unicancer (UCBG) ASSEMBLÉE GÉNÉRALE - programme Mercredi 16 novembre de 19h00 à 21h00, au Palais des Congrès à Dijon (3 boulevard de Champagne - 21078 DIJON CEDEX) Salle Santenay-Chablis 19h00-19h10 : Stratégie du groupe (S. Delaloge) 19h10-19h40 : Résultats d’études du groupe en avant-première de SABCS ADENDOM (S. Delaloge) UCBG 2-14: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict[reg] (EPclin[reg]) clinico-genomic test on treatment decision making among patients with intermediate clinical risk CARMINA02 (F. Lerebours) Genomic analysis to evaluate response to neoadjuvant anastrozole and fulvestrant in postmenopausal ER-positive HER2-negative breast cancer patients included in the UCBG CARMINA02 trial GRT02-COMET (J.Y. Pierga) Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study 19h40-20h10: Essais en phase de lancement ULTIMATE (F. André) A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible to Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant OPTIGEN (R. Rouzier) Prospective multicenter randomized study assessing genomic test impact on shared decision of adjuvant chemotherapy in patients with ER-positive, Her2-negative early breast cancer with uncertainty on the indication of chemotherapy using standard assessments PADA-1 (F.C. Bidard) PAlbociclib and hormone therapy as first line treatment for metastatic hormone-positive HER2negative breast cancer: Efficacy, Safety and utility of Circulating ESR1mutation detection 20h10-20h35 : Actualité des essais en cours RxPONDER (S. Delaloge); UNIRAD (T. Bachelot); SAFIR2 (F. André); NEOPAL (P. Cottu) HYPOG01 (S. Rivera) 20h35-20h50 : Actualité du groupe des chirurgiens 15min (C. Coutant) 20h50 : Conclusion de la journée (S. Delaloge) [21H00] Clôture de la séance v4 08/11/2016